In the early 1980s, Cliff Morrison did what no other San Francisco General Hospital staff member had the guts to do: come up with a humane way to treat and care for AIDS patients. We sat down with him to learn more about the life-changing initiative—and how the legacy of Ward 5B lives on.
The human touch.
It seems like such a simple thing, but for San Francisco General Hospital nurses and doctors in the early 1980s, putting their hands on patients suffering from what was known at the time as “gay cancer” was unthinkable.
In the past two decades, incredible progress has been made in the fight against HIV in the United States. Through a steady stream of innovation, more people living with HIV are leading longer, healthier lives. But the work is far from over. According to the CDC, as of 2014, 45 percent of people living with HIV in the U.S. are now 50 years old or older, and by 2020 that percentage is estimated to reach 70 percent.
New Initiative Mobilizes Local Communities to Implement Solutions
FOSTER CITY, Calif., Dec. 4, 2017 /3BL Media/ -- Gilead Sciences, Inc.(NASDAQ:GILD) today announced the launch of the Gilead COMPASS (COMmitment to Partnership in Addressing HIV/AIDS in Southern States) Initiative, a 10-year, $100 million commitment to support organizations working to address the HIV/AIDS epidemic in the Southern United States.
FOSTER CITY, Calif., May 2, 2018 /3BL Media/ — Gilead Sciences, Inc. today announced the release of its 2017 Year in Review, composed of its Annual Report and Corporate Social Responsibility report. The Year in Review provides a comprehensive view into the company’s achievements and highlights how it has continued to deliver on its mission to improve the lives of people living with life-threatening diseases.
EJAF has announced new funding initiatives to increase advocacy and service delivery for people living with and at-risk for HIV and hepatitis C.
Funding for the new initiatives will be supported by EJAF and include financial contributions from Gilead Sciences. Gilead will also provide a donation of hepatitis C products to cure 5,000 patients – a critical contribution in a region where up to 97% of people living with HIV are co-infected with hepatitis C.
FOSTER CITY, Calif., Oct. 25, 2017 /3BL Media/ -- Gilead Sciences, Inc.(NASDAQ:GILD) announced the second round of recipients of its HIV cure grants program. This new commitment will provide $7.5 million to support five additional HIV cure research initiatives led by top academic institutions and focused on translational research and efficacy studies in preclinical models.
Funds to support results-driven research and community projects engaged in HIV cure activities
FOSTER CITY, Calif., January 11, 2017 /3BL Media/ -- Gilead Sciences, Inc.(Nasdaq:GILD) today announced the recipients of its HIV cure grants program, a fund totaling more than $22 million, which will support 12 new HIV cure research projects.
How a software donation and pro bono volunteers are helping nonprofit SHIP track budgets and expenses related to their work to bring dignified care to people living with HIV
It was while serving as an infectious diseases fellow caring for HIV and AIDS patients at Philippine General Hospital that Dr. Kate Leyritana first began to recognize the barriers that stopped people from getting tested and receiving care once diagnosed with HIV.
Quest contributes to the fight against AIDS in a variety of ways. In 2015, we marked AIDS Day by participating in a number of events across the country, sponsored AIDS Walks and other fundraising events, and raised awareness about the disease.